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ABSTRACT
Background: Genetic intratumoral heterogeneity (ITH) hinders biomarker 
development in metastatic clear cell renal cancer (mccRCC). Epigenetic relative to 
genetic ITH or the presence of consistent epigenetic changes following targeted 
therapy in mccRCC have not been evaluated. The aim of this study was to determine 
methylome/genetic ITH and to evaluate specific epigenetic and genetic changes 
associated with sunitinib therapy. 
Patients and methods: Multi-region DNA sampling performed on sequential 
frozen pairs of primary tumor tissue from 14 metastatic ccRCC patients, in the Upfront 
Sunitinib (SU011248) Therapy Followed by Surgery in Patients with Metastatic Renal 
Cancer: a Pilot Phase II Study (SuMR; ClinicalTrials.gov identifier: NCT01024205), 
at presentation (biopsy) and after 3-cycles of 50mg sunitinib (nephrectomy). 
Untreated biopsy and nephrectomy samples before and after renal artery ligation 
were controls. Ion Proton sequencing of 48 key ccRCC genes, and MethylCap-seq 
DNA methylation analysis was performed, data was analysed using the statistical 
computing environment R. 
Results: Unsupervised hierarchical clustering revealed complete methylome 
clustering of biopsy and three nephrectomy samples for each patient (14/14 
patients). For mutational status, untreated biopsy and all treated nephrectomy 
samples clustered together in 8/13 (61.5%) patients. The only methylation target 
significantly altered following sunitinib therapy was VHL promoter region 7896829 
which was hypermethylated with treatment (FDR=0.077, P<0.001) and consistent 
for all patients (pre-treatment 50% patients had VHL mutations, 14% patients VHL 
hypermethylation). Renal artery ligation did not affect this result. No significant 
differences in driver or private mutation count was found with sunitinib treatment. 
Conclusions: Demonstration of relative methylome homogeneity and consistent 
VHL hypermethylation, after sunitinib, may overcome the hurdle of ITH present at 
other molecular levels for biomarker research.
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INTRODUCTION
A number of driver genes have been identified in 
clear cell renal cell cancer (ccRCC) [1-3]; but mutations 
to the von Hippel Lindau (VHL) gene remain the crucial 
driver mutation in the development of ccRCC [3]. 
However, mutations of VHL and downstream angiogenic 
genes do not predict response to vascular endothelial 
growth factor (VEGF) targeted therapy [4]. Indeed none 
of the established ccRCC driver mutations have been 
implicated in resistance to targeted therapy. Genetic 
intratumoral heterogeneity (ITH) in ccRCC is thought to 
play a role in the evolution of treatment resistance and 
hinders biomarker development due to inherent variably 
[3, 5, 6]. 
VHL mutations are identified in 39-85% of sporadic 
ccRCCs [7-10]; tumors which lack mutations in VHL 
appear to have epigenetic changes or loss of heterozygosity 
(LOH) at the VHL locus [7]. Therefore, inactivation 
of VHL occurs in up to 98% ccRCCs. Recent in vitro 
work by Vanharanta and colleagues has added intriguing 
functional context to the role of VHL in metastatic ccRCC 
(mccRCC). They identified that activation of metastasis-
driving genes downstream of VHL-HIF, were enabled 
by epigenetic events [11]. Therefore dynamic epigenetic 
changes, particularly to VHL and other driver mutations, 
could contribute to resistance to targeted therapy in 
mccRCC. 
Here we report the effects of sunitinib on mutation 
and methylation of these driver genes to provide evidence 
for predictive biomarkers and mechanisms of resistance. 
For this analysis, sequential ccRCC tumor samples 
before and after sunitinib therapy, from mccRCC patients 
within a prospective trial were employed. MethylCap-
seq methylation analysis, to detect any highly methylated 
regions in the genome, with accompanying focused 
mutation analysis was performed. The study aims were 
to investigate (i) methylome and genetic ITH; and (ii) 
consistent epigenetic and genetic changes associated with 
sunitinib. We hypothesised that: (i) significant methylation 
changes occur with treatment that may be associated with 
development of resistance to sunitinib therapy; and (ii) 
there will be a reduction in private mutations (somatic 
mutation present in only one of the biopsy or nephrectomy 
samples for a given patient) following sunitinib therapy 
due to clonal selection.
RESULTS
Patient demographics
DNA from sequential fresh frozen tissue samples 
was available from 14 patients in the SuMR trial. The 
characteristics of the patients included in this study are 
given in Supplementary Table 1 and compared to other 
patients in the trial from whom sequential tumor DNA was 
not available. 
Sequencing and methylation summary results
Sequencing of 48 ccRCC genes, related to renal 
cancer pathogenesis and mechanism of action of agents 
used in treatment of mccRCC, as listed and detailed in 
Supplementary Table 2 was performed. The panel was 
259.3 Kb in size, contained 1,193 amplicons and gave 
98.36% coverage of the submitted genes (Supplementary 
Table 3 details sequencing summary statistic). The 
somatic mutations and candidate drivers are listed in 
Supplementary Table 4 and CNVs relative to normal 
samples in Supplementary Table 2. In terms of mutations 
to the commonest ccRCC tumor suppressor genes, 
baseline mutations (in the untreated samples) were found 
at the expected frequency, other than for SETD2 which 
was higher than expected (expected proportion 11%) [10]: 
VHL mutation in 6 of the 12 patients for whom germline 
DNA was available (50%; Supplementary Table 5), 
PBRM1 in 4 patients (33.3%), BAP1 in 3 patients (16.7%) 
and SETD2 in 6 patients (41.7%). There were no CNVs 
identified for any of VHL, PBRM1, BAP1 or SETD2. 
Supplementary Table 6 details the MethylCap-seq 
data, revealing low (particularly for the biopsies) yet 
workable coverages for the different samples.
Hierarchical clustering of methylation and 
mutational data
Figure 1 shows hierarchical clustering of the 48 key 
gene mutations (Figure 1a and Supplementary Figure 1) 
and the 1,000 gene loci featured by the largest methylome 
variance (Figure 1b), for the biopsy and multiple samples 
at nephrectomy. As previously shown, the clustering 
results reveal complete methylome clustering of biopsy 
and three nephrectomy samples for each individual patient 
(14/14 patients) [12]. Mutational analysis revealed only 8 
of 13 (61.5%) patient’s samples clustered. A further 4 of 
13 (30.8%) patient samples partly clustered, while there 
was no clustering in 1 patient sample. 
Methylation differences for targets following 
sunitinib treatment
We next explored methylation differences for the 48 
key target genes following sunitinib treatment (Figure 2a). 
This supervised approach was preferred to a genome-wide 
approach that limits the study power, as putatively less 
informative loci will lead to a substantial increase of the 
number of hypotheses tested. VHL was the only target that 
has a false discovery rate (FDR) under the 0.1 significance 
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level (FDR = 0.077, P < 0.001). The logFC was 0.8734 
(Supplementary Table 7) implying that the post-treatment 
samples were more methylated than the untreated biopsy 
samples. This was only the case for the methylation core 
in the VHL promoter region 7896829 (located from nt 
10183068 to nt 10183220); other VHL regions were not 
significantly differentially methylated. 
Taking “Medium to high” and “High to very 
high” levels of methylation as hypermethylated, 14% of 
patients had hypermethylation at VHL region 7896829 
pre-treatment, and 64% post-treatment (Supplementary 
Table 5). When assessed on a per-patient basis (Figure 
2b), there was variation in baseline VHL region 7896829 
methylation. The normalized VHL methylation level 
for the biopsy sample had a mean of 1.8 and standard 
deviation of 1.1. However, for all patients VHL 
methylation at region 7896829 was greater in the post-
treatment nephrectomy samples than the pre-treatment 
biopsy sample. Furthermore, when assessing the response 
of each patient to sunitinib there was no significant 
difference in the extent of VHL hypermethylation between 
those patients who had a favourable vs poor response to 
sunitinib (P = 0.896, student’s t-test; Figure 2b). 
Figure 1: Hierarchical clustering dendrograms of methylation and mutational data. a. Unsupervised hierarchical clustering 
of patient sample mutations. 8/13 (61.5%) patient biopsy and nephrectomy samples clustered completely and 4/13 (30.8%) clustered partly 
together. Supplementary Figure 1 shows the mutational heatmap. b. Hierarchical clustering of DNA methylation data. The analysis was 
performed on 14 matched pairs of untreated (biopsy) and treated (nephrectomy tissue). The 1,000 loci featured by the largest variance (after 
quantile normalization and log transformation) were used for clustering, employing complete clustering based upon Euclidean distance. For 
all 14 patients their biopsy and nephrectomy samples were found to cluster. Figure amended from (12) with permission.
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Methylation difference for targets following 
differing sampling conditions
In order to eliminate potential impact of sampling 
procedure, the VHL region was also evaluated in the 
control hypoxia sample set, taken just prior and following 
renal artery ligation. There was no effect of sampling 
identified on VHL methylation at location 7896829 (P 
= 0.46, logFC = -0.3151, FDR = 0.76). Furthermore, 
the negative FC clearly contrasts with the consistently 
higher methylation degree observed for treated samples, 
thereby refuting a mere impact of different sample sizes 
(Supplementary Figure 2). Therefore, it can be concluded 
Figure 2: Methylation differences for targets following sunitinib treatment. a. Comparison of biopsy and nephrectomy for 
all patients. Target label displayed in each subplot. False discovery rate (FDR) is provided in parenthesis. NA = no methylation core was 
present, either because the target’s regions were filtered due to low average counts, or because no methylation cores were present for the 
target in the methylome map. If there was more than one region for a certain target, the Figure only shows the most significantly differential 
region according to P-value. VHL is the only target that has FDR under the 0.1 significance level (i.e. 0.077). The P-value is 0.00086 and 
the logFC -0.8734. The latter implies that the post-treatment samples are more methylated in average than the pre-treatment ones. This is 
only the case for the methylation core in the VHL promoter region 7896829 located from nt 10183068 to nt 10183220 on chromosome 3; 
other VHL regions are not found to be differentially methylated under this significance level. b. Per patient methylation of VHL at region 
7896829. For all samples methylation was greater in the post-treatment nephrectomy samples than the pre-treatment biopsy. Results 
divided into patients who had a good or poor response to treatment, there was no significant difference in the VHL hypermethylation seen 
in patients with a good vs poor response to sunitinib (P = 0.896, Student’s t-test). 
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that the difference found following sunitinib therapy was 
not due to the hypoxia effect on the tumor from ligation of 
the renal artery to fresh sample acquisition. Supplementary 
Table 8 show for this sample set the methylation 
differences for all the targets. There is no region that has 
a significant difference under the FDR < 0.1 significance 
level.
Mutation frequency alterations following 
treatment
A comparison of the frequency of candidate 
driver mutations in the treated and untreated samples 
showed no significant changes associated with therapy 
(Figure 3a and Supplementary Table 9). There was no 
significant change in the number of CNVs found from 
untreated to treated samples (P = 0.57, paired Student 
t-test; Supplementary Table 10), agreeing with the 
evidence from small mutations. Further analysis showed 
no significant differences in overall frequency of private 
mutations (t-test, P = 0.2) (Figure 3b and Supplementary 
Table 11) on a per-patient basis, countering the hypothesis 
that clonal selection will result in a reduction in private 
mutations. 
Loss of heterozygosity (LOH)
LOH was observed in some samples (supplementary 
Figure 3, Supplementary Table 12). In these regions, the 
B-allele frequency (BAF) of germline heterozygous SNPs 
was clearly shifted away from the expected 0.5, but in no 
case was it observed to shift entirely to 0 or 1. This could 
be due to sample purity (normal cells), but given the other 
observations of ITH, it is more likely to be sub-clonal. In 
some patient samples LOH was observed in post-treatment 
samples only, indicating development following therapy 
(i.e. SU06 chr10), there were no consistent patterns that 
might account for resistance mechanisms. We observed 
recurrent LOH of chromosome 3p, consistent with 
previous reports which showed near universal 3p LOH [3, 
5, 13]. Due to the probable sub-clonal nature of the LOH 
regions detected, we excluded them from further analysis.
Phylogenetic tree analysis
Phylogenetic trees were generated from the genetic 
mutation data (CNV, Indel and SNVs) (supplementary 
Figure 4 and Supplementary Tables 4 and 13). There were 
truncal mutations in VHL, PBRM1, BAP1, SETD2 in 6/13 
tumors. The results showed no consistent inter-patient 
features for the untreated biopsy samples and a high 
degree of variability within different tumors supporting 
the hypothesis of polyclonal evolution in mRCC and little 
effect of treatment on this process. 
DISCUSSION
In this study, using a rare sample set of matched 
Figure 3: Driver mutation comparison between biopsy and nephrectomy samples. a. Mean number of SNV/indel candidate 
driver mutations per gene across all biopsy (15) and nephrectomy (44) samples. Some genes have multiple candidate driver mutations in 
some samples. Putative passenger somatic mutations are not included. There were no significant differences in mutation count between 
biopsy and nephrectomy samples (two-sided Wilcoxon rank sum test, P≥0.05 for all genes). b. Dot plot of private mutation frequency 
in biopsy and nephrectomy samples. Median value indicated. The number of mutations was greater in the biopsy sample for 7 patients, 
nephrectomy in 4 samples and equal between biopsy and nephrectomy in 2 samples. There was no significant difference in the number 
of private mutations in the biopsy samples compared with the median number of private mutations in the nephrectomy samples (P = 0.2, 
unpaired t-test).
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fresh frozen pre- and post-sunitinib treated ccRCC 
samples, dynamic epigenetic changes to VHL were 
identified. There was also complete epigenetic clustering 
of all samples taken from the same patients, suggesting 
relative homogeneity of the methylome. Together these 
findings suggest that consistent methylation alterations 
may be an attractive field for biomarker research. 
In order to evaluate the potential of DNA 
methylation as a more stable readout in the process of 
response and acquisition of resistance to targeted therapy, 
the change in methylation status of the 48 ccRCC related 
genes were evaluated. A genome-wide approach could 
have been performed but limits the power, as putatively 
less informative loci will lead to a substantial increase 
of the number of hypotheses tested. Interestingly, VHL 
methylation status was the sole gene, of the 48 evaluated, 
which was significantly altered following sunitinib 
treatment. VHL hypermethylation was consistent when 
considering all biopsy vs all nephrectomy samples and 
also on a per-patient basis. The finding of significant 
changes to VHL, which is intrinsic to ccRCC, underlines 
the potential of this platform for future research. 
It has been established that the procurement 
conditions for fresh tumor tissue can greatly affect gene 
and protein expression [14]. Therefore we collected two 
paired control samples (biopsy and nephrectomy) in which 
no sunitinib was given to ensure these findings were not 
purely representative of the subtle differences in sample 
collection. No significant changes to VHL methylation 
were seen in these 2 pairs implicating sunitinib. A lack 
of power is an unlikely alternative explanation, as the 
non-significant effect was in a different direction to that 
consistently associated with sunitinib treatment. 
It is likely that the change to VHL methylation is 
due to sunitinib rather than progression of the disease; 
agreeing with previous work refuting a link between 
VHL inactivation and aggressive ccRCC [8]. Analysis 
of biopsy tissue prior to sunitinib showed a high degree 
of VHL methylation variability. A relatively short period 
of treatment resulted in an increase in methylation 
in all samples, implicating a treatment effect. This 
finding is supported by preclinical and clinical data also 
demonstrating hypermethylation and downregulation of 
key tumor suppressor genes (PTEN) in leukaemia and 
GISTs [15-17]. Vanharanta et al analyzed metastatic 
subpopulations of VHL-deficient ccRCC cells and 
demonstrated that during ccRCC progression there were 
epigenetic alterations in the VHL-HIF pathway, these 
alterations were associated with metastasis and a poor 
prognosis [11]. In congruity with the work of Vanharanta, 
the data presented in this manuscript, show consistent VHL 
hypermethylation (above any baseline VHL methylation 
levels) following a 18-week period of treatment with 
sunitinib. This consistent molecular change allows further 
hypotheses to be developed with regard to predictive 
ability of VHL methylation and also the role of VHL 
methylation in the development of acquired resistance to 
sunitinib. 
Genetic mutational analysis showed clustering of 
pre-treatment biopsy and all post-treatment nephrectomy 
samples only occurred in 61.5% patients. Additionally, 
the phylogenetic trees illustrate relative homogeneity 
of mutation status between biopsy and nephrectomy 
samples, but variability between samples from the same 
patient. Furthermore, LOH analysis showed the presence 
of LOH across the sample set, but at a subclonal level 
only and without consistency between untreated and 
treated samples. As such, there was genetic ITH when 
considering the somatic mutations (SNPs, indels, and 
CNVs) found in 48 key ccRCC genes in the biopsy and 
multi-region sampling of the post-treatment nephrectomy 
sample. Assessment of driver mutations alone, revealed no 
significant differences in mutation counts between biopsy 
and nephrectomy samples. These data confirm genetic ITH 
and a failure to identify consistent genetic biomarkers in 
mccRCC, as we and others have demonstrated previously 
[3, 6]. It was hypothesized that there would be a reduction 
in private mutations following sunitinib therapy, due 
to a process of clonal selection. This hypothesis was 
not proven, as private mutation status was comparable 
before and after sunitinib treatment. As such, the 18-week 
sunitinib treatment period does not have an obvious effect 
on private mutation frequency and has little effect on the 
baseline level of genetic ITH. It may be that genetic clonal 
evolution with sunitinib takes longer to develop and the 
tissue collection at 18 weeks was premature. 
This study has a number of important strengths, 
including: access to a very rare sample set of matched 
pre- and post-sunitinib treatment ccRCC samples 
(meaning validation was not possible), control samples 
to ensure renal artery ligation was not responsible for the 
methylation results identified, and the high throughput 
analyses employed. However, we are also aware of the 
study shortcomings: the specific timing of sunitinib 
treatment, limitations of a single biopsy versus the 
multiregion sampling of the nephrectomy specimen, and 
targeted sequencing of only 48 genes preventing direct 
comparisons of mutational and methylation clustering. 
The significant result for VHL illustrates that the limited 
MethylCap-seq coverages were still workable. The 
collection of sequential tumor tissue for epigenetic 
analysis has proven challenging in RCC. This is reflected 
by the lack of literature in this setting or on methylation 
as a potential biomarker in mccRCC . Our work aimed to 
explore if the dynamic epigenetic changes with sunitinib 
were as complex and variable as those seen with DNA, 
and was successful in that respect. It was not powered 
to define predictive biomarkers, which would require 
hundreds of patients each with potentially multi-region 
tumor sampling. A crude comparison of responders and 
non-responded showed no difference in VHL methylation 
levels following therapy. Whether these findings would 
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apply at different time points or at progression should be 
the focus of future work.
There is evidence from TGCA data to show 
biological relevance to the VHL methylation demonstrated 
in this study. There is no TCGA data (based on Infinium 
HumanMethylation microarrays) on ccRCC for the region 
picked up by our analysis, (www.mexpress.be [VHL 
gene symbol, KIRC dataset]). However, when looking 
at other tumors (profiled using the more recent HM450 
version of the array, e.g. in colon adenocarcinoma dataset, 
COAD, HM450 data for a subset of the tumors), 3 probes 
targeting the VHL region of described in our work (i.e. 
cg10352003, cg06034437 and cg01998262), exhibit 
clear methylation. Moreover, for the middle probe there 
is proof of a significant (negative) association between 
methylation and expression (COAD dataset); furthermore, 
this association is the strongest of all VHL probes. Finally, 
for cg10352003, differential methylation was already 
demonstrated in a prostate cancer context [18]. The 
data presented in the current study showed significant 
consistently increases in VHL methylation in all 13 paired 
samples after a short period of sunitinib. In view of the 
mode of action of sunitinib and the pathogenesis of ccRCC 
this finding is likely to have mechanistic importance in 
our understanding of the effect of sunitinib at a molecular 
level. These findings occurred in responders and non-
responders alike, suggesting a more global effect on 
the tumor rather than a predictive type biomarker. One 
might expect that those patients with functional VHL may 
develop hypermethylation as a mechanism of resistance to 
sunitinib. However, VHL hypermethylation with sunitinib 
occurred in patients with wild-type and those with mutant 
VHL; thus, one can speculate that VHL hypermethylation 
is a mechanism of global resistance rather than a unique 
phenomenon associated with rare cases where VHL is not 
altered. However larger studies with multiple biopsies at 
more time points would be required to define predictive 
biomarkers. It may be that biopsies taken at progression, 
as well as after an initial period of therapy, gives better 
insight into the biology of treatment failure. 
Our findings provide insight into the dynamic and 
consistent epigenetic changes occurring with sunitinib. 
The hurdles that genetic, transcriptomic and proteomic 
heterogeneity provide to biomarker exploration in ccRCC 




Primary tumor tissue (the “sunitinib set”) was 
collected and snap frozen from mccRCC patients treated 
with three cycles of pre-surgical sunitinib (Sutent™, 
Pfizer, Sandwich, UK), for 18 weeks, as a translational 
endpoint of a previously reported prospective clinical 
trial (SuMR; NCT01024205) [19]. The clinical trial 
and subsequent genetic analysis has appropriate ethical 
approval (REC: 07/Q0603/58). Patient matched tissue 
was taken at two time points from the primary renal tumor 
(at baseline and after 18 weeks of therapy), the latter at 
the time of cytoreductive nephrectomy. As described 
previously, to address ITH, multiple spatially separate 
tumor samples (n = 3) were taken at the 2nd time point 
approximately 30 minutes following ligation of the renal 
artery [6]. Thus, for each patient there were intended to be 
four cancer samples. Normal renal tissue was also sampled 
to provide normal genomic DNA.
To evaluate the effect of tumor hypoxia on 
molecular changes, an additional patient matched sample 
set (the “hypoxia set”) was obtained from two patients. 
These samples were obtained as part of the Scottish 
Collaboration On Translational Research into Renal Cell 
Cancer (SCOTRRCC) study (East of Scotland Research 
Ethics Service REC 1: 10/S1402/33). These patients, 
who were undergoing open cytoreductive nephrectomy 
for mccRCC, had fresh primary ccRCC tumour biopsies 
taken prior to ligation of the renal artery and then further 
matched fresh frozen tumor samples harvested following 
ligation and division of the renal artery and removal of 
the kidney. This hypoxic set acted as a control for the 
sampling methodology. 
DNA extraction
Frozen section histology was performed to ensure 
that the tissue used for DNA extraction contained 
viable ccRCC tissue. Genomic DNA extraction was 
undertaken using the Qiagen DNeasy Blood and Tissue 
(Qiagen, Manchester, UK) kit as per the manufacturer’s 
instructions. 
Sequencing
A custom Ampliseq panel (Thermo Fisher Scientific, 
Paisley, UK) was designed to assess 48 key ccRCC 
genes in 63 samples across 13 patients for which DNA 
samples remained following the methylome analysis. 
Eleven patients had all five associated samples (normal, 
biopsy (Bx), and three post-treatment nephrectomy (Nx)), 
one patient (SU16) had all but the normal sample, and 
one patient (SU54) had only two nephrectomy samples. 
Multiplex PCRs were performed according to the 
manufacturer’s instructions across two primer pools. The 
samples were sequenced on an Ion Proton sequencer to 
a mean on-target depth of 4000X with 97-98% of bases 
over 15X. Samples were aligned to the hg19 human 
genome reference assembly and variants identified with 
TorrentSuite 4.2 (Thermo Fisher Scientific). Sequencing 
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data is available via NCBI SRA (Accession number 
SRP056914).
Variant filtering and annotation
Variants were filtered to exclude those with genotype 
quality < 60 or variant allele frequency < 10% (summed 
over all alternate alleles), or located within 1bp of a 
homopolymer run of at least 4bp. The remaining variants 
were grouped by patient and classified by the degree of 
sharing of genotypes (Supplementary Table 13). Variants 
with non-reference genotypes occurring only in the 
tumour samples for a given patient, and not occurring in 
any normal samples across the patient set were considered 
tumour-specific somatic mutations. Ensembl Variant Effect 
Predictor [20] was used to annotate the somatic mutations. 
Frameshift, in-frame deletion, missense, nonsense (stop 
gained), splice acceptor, and splice donor mutations 
were considered candidate driver mutations. Missense 
mutations predicted to be at least possibly or probably 
damaging by at least one of SIFT [21] or Polyphen 2 [22] 
were also considered candidate driver mutations.
Copy number variation
EXCAVATOR 2.2 [23] was modified to handle 
targeted sequencing input and used to infer copy number 
variants by comparing normalized target coverage between 
the tumour (biopsy and nephrectomy) and normal samples. 
CNVs were identified for the 12 patients with a normal 
sample (excluding SU16) (Supplementary Table 13).
Loss of heterozygosity
Bi-allelic SNPs that were clearly heterozygous (B 
allele frequency (BAF) between 0.4 and 0.6 inclusive) in 
the normal sample for a patient were selected (excluding 
SU16). Reads supporting each allele were counted directly 
from the BAM files for all samples for the patient. BAFs 
for the tumour samples were calculated and plotted in R, 
and ExomeCNV [24] was used to identify regions of LOH 
(Supplementary Table 12).
Clustering and phylogenetic trees
Samples were clustered according to their somatic 
mutations (SNPs, indels, and CNVs) using the R packages 
ape 3.1-1 and igraph 0.7.1 [25, 26]. For each individual 
patient, we calculated a Manhattan distance matrix and 
generated a phylogenetic tree using the bionj algorithm 
implemented in the R package ape [25, 27]. Branches were 
labelled with candidate driver mutations (SNPs, indels, 
and CNVs) that were consistent with the tree.
DNA methylation analysis
DNA methylation analysis (MethylCap-seq) was 
performed as outlined previously [28], except that solely 
the MethylCap kit (Diagenode, Liège, Belgium) was used 
for capturing methylated fragments from 500ng starting 
material and that massively parallel sequencing of these 
fragments was subsequently performed on the Illumina 
HiSeq 2000 (Illumina, San Diego, CA, USA). Methylation 
data is available via GEO (Accession number GSE67700). 
Methylation data processing and analysis
Raw data files were mapped with BOWTIE on 
human reference genome Hg19/GRCh37, and summarized 
using an in-house developed Map of the Human 
Methylome (http://www.biobix.be/map-of-the-human-
methylome/mhm-version-2/) consisting of a putatively 
genome-wide overview of potentially methylated loci 
(“methylation cores”). Further data analysis was performed 
with Python 3.4.1 and R 3.0.1. The Bioconductor LIMMA 
package (3.16) was used to identify regions featured by 
differential methylation (applying quantile normalization). 
LIMMA was originally a library for microarray analysis, 
but the voom function that was used also allows for 
sequencing count data analysis, and is particularly suitable 
in case of library size differences [29].
For both the main and the hypoxia dataset, only 
methylation cores that referred to annotated promoter 
regions (including exon1) and had at least an average 
coverage of one mapped fragment per core were used 
for analysis with voom and LIMMA. Low coverage 
loci are featured by insufficient power to be detected as 
differentially methylated and were removed from the final 
dataset to avoid inflation of the number of hypotheses 
tested. The final fit to determine differential methylation 
was obtained with the LIMMA functions lmFit and 
eBayes. Methylation cores corresponding to the target 
genes were subsequently selected for P-value and FDR 
estimation (Benjamini-Hochberg), an FDR significance 
threshold of 10% was selected. 
For the 48 key targets, a per-patient analysis was 
also performed. First, the quantile segments of all the 
normalized counts were determined for the region, in 
order to have four categories of counts: ‘No to low 
methylation’, ‘Low to medium’, ‘Medium to high’, and, 
‘High to very high’. Then, for each patient, the pre- and 
post-treatment condition was determined based on their 
average methylation count. ‘Medium to high’ and ‘High 
to very high’ were both taken as hypermethylated state.
The methylation data was also used to for an 
unsupervised hierarchical clustering analysis of the 
samples. The 1,000 loci featured by the largest variance 
(after quantile normalization and log transformation) were 




Unpaired student T-test and Chi-squared test 
were used to compare continuous and categorical data 
respectively. 
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